BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Cromakalim

A potassium-channel opening vasodilator that has been investigated in the management of hypertension. It has also been tried in patients with asthma. (Martindale, The Extra Pharmacopoeia, 30th ed, p352)

300+ PubMed studies analyzed · 3 RCTs · Evidence Score: 44.6

Research Domains

Cromakalim has been studied across 16 research domains including ❤️ Cardiovascular, ⚡ Energy & Fatigue, 🦴 Bone & Joint, 🧠 Focus & Attention, 🔥 Metabolic. The primary research focus is ❤️ Cardiovascular with 24% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Cromakalim, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Nicorandil
2 shared targets
Tolbutamide
2 shared targets
tetramethylpyrazine
2 shared targets
Glyburide
5 shared targets
Chlorpropamide
2 shared targets
Raclopride
2 shared targets
propyl
2 shared targets
palmidrol
2 shared targets
Linezolid
2 shared targets
Warfarin
2 shared targets
Loading evidence profile...

This evidence profile for Cromakalim is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.